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1. INTRODUCTION  
 
Neuroblastoma 
 
Neuroblastoma accounts for more than 7% of malignancies in patients younger 
than 15 years and around 15% of all pediatric oncology deaths. It is the most common 
extra cranial solid tumor in childhood and the most frequently diagnosed neoplasm 
during infancy. This disease is remarkable for its broad spectrum of clinical behavior. 
Although substantial improvement in outcome of certain well-defined subsets of patients 
has been observed during the past few decades, the outcome for children with a high-
risk clinical phenotype has improved only modestly, with long-term survival still less than 
40% (1). 
The genetic aberration most consistently associated with poor outcome in 
neuroblastoma is genomic amplification of MYCN (2, 3, and 4).  MYCN amplification 
occurs in roughly 20% of primary tumors and is strongly correlated with advanced stage 
disease and treatment failure. Its association with poor outcome in patients with 
otherwise favorable disease patterns such as localized tumors or INSS stage 4S disease 
underscores its biological importance. 
Although initially responsive to chemotherapy, neuroblastoma often becomes 
drug resistant, leading to relapse, that is the most common cause of death. Little 
progress has been made with regards to survival rates over the past 5 to10 years, 
despite intensive chemotherapy and radiation intervention at maximum levels. Improving 
metastatic neuroblastoma's dismal survival rates remains a major challenge in pediatric 
oncology and will only result from specifically targeted molecular therapies founded on a 
better understanding of the molecular determinants of neuroblastoma. 
Amplification of MYCN occurs in a substantial subset of neuroblastomas with 
high mortality, although the basis for this effect is enigmatic. Compelling data 
demonstrate the ability of deregulated MYCN to sensitize cells to apoptosis following 
loss of mitogenic signals or genotoxic damage. Therefore, it is speculated that evasion 
of MYCN primed apoptosis is mandatory for neoplastic progression in neuroblasts with 
MYCN amplification. This evasion is likely to result from early cooperating mutations that 
activate survival pathways or inhibit apoptosis pathways. These signaling pathways have 
not been fully characterized with deregulated MYC, and are even less well understood 
for MYCN. Understanding this process, and how it is evaded in neuroblasts with MYCN 
5 
 
amplification, may have far ranging implications since traditional anti-neoplastics engage 
cellular apoptosis machinery to exert their cytotoxic effects. Defects in the regulation or 
engagement of apoptosis, as selected for in neoplastic cells with deregulated MYCN, 
can render these cells intrinsically resistant to therapy. Novel biological therapeutics 
targeting these pathways may restore sensitivity to both the inherent death-priming 
function of deregulated MYCN and to traditional anti-neoplastic agents. 
Neuroblastoma detection in early life or in utero suggests that early disruption of normal 
developmental processes plays a part in tumour initiation. Insight into the molecular 
regulation of noradrenergic development has shed light on many facets of neuroblast 
biology and might lead to the identification of novel targets.  
Similarly, an emerging appreciation for the role of cancer stem cells in 
propagating malignant disease could prove especially helpful in understanding and 
treating embryonal tumours such as neuroblastoma. Evidence suggests that 
malignancies can arise or be maintained in a stem cell compartment with the attributes 
of limitless replication and self-renewal. The Notch, Sonic hedgehog, and Wnt/β-catenin 
developmental programmes play a crucial part in stem cell determination and renewal in 
diverse tissues and misappropriation of these pathways seems to be a recurring theme 
in embryonal tumourigenesis (5, 6).  β-catenin signaling is involved in the maintenance 
and expansion of neural crest stem cells and neural progenitors. An engineered gain-of-
function β-catenin allele targeted to neural tissues causes marked neural progenitor 
expansion by promoting cell cycle entry at the expense of differentiation (7). This 
pathway might contribute to maintenance of neuroblastoma stem cells as well, raising 
the question of whether emerging inhibitors of this pathway might have therapeutic 
usefulness.  
Overall, improved understanding of normal neurodevelopment of the 
sympathicoadrenal system will help us identify the key mutational events that initiate 
neuroblastoma tumorigenesis. Defining these events, as well as those that reliably 
predict for the acquisition of a high-risk phenotype, might ultimately direct us to the key 
pathways that can be exploited therapeutically. 
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P53 and Neuroblastoma 
 
The p53 tumor surveillance network constitutes the core defense mechanism of 
the cell against loss of genomic integrity and malignant transformation. Evasion of p53 
activity is, therefore, a prerequisite for tumor cells to survive and thrive, and this is 
attainable either through mutation of the TP53 gene or through defects in the molecular 
components that govern or execute the various aspects of the p53 response. Elucidation 
of the mechanisms by which tumor cells override the p53-orchestrated failsafe program 
is not only important to gain insight into the ontogenesis of a tumor, but may also point to 
preferable modes of therapeutic intervention.  
Approximately half of human cancers have inactivating mutations of p53 (known 
as TP53 in human), and most of the remaining malignancies deactivate the p53 pathway 
by increasing its inhibitors, reducing its activators or inactivating its downstream targets. 
p53 is best characterized as a transcription factor that binds to specific DNA sequences 
and transactivates a number of genes with a variety of functions including cell cycle 
arrest, apoptosis, causing changes in metabolism and others. 
In addition to this nuclear activity, p53 also possesses biological activities that 
are cytosolic and transcription-independent. Several years ago it was noted that 
overexpression of a mutant p53, lacking most of the DNA-binding domain (DBD) and 
completely deficient in transactivation function, could nonetheless trigger apoptosis. 
Indeed, overexpression of a variety of transactivation-incompetent p53 mutants can 
efficiently induce apoptosis in human cells (8). 
A striking feature of the childhood cancer neuroblastoma is the low frequency 
(<2%) of TP53 mutations at diagnosis (9). There is considerable evidence that TP53 
mutations may be acquired during chemotherapy and malignant progression of 
neuroblastoma. 
Accordingly, an increased frequency of TP53 mutations is observed in multidrug-
resistant neuroblastoma cell lines and in neuroblastoma cell lines established at relapse, 
but even in this context, the majority of cell lines remain characterized by a wild-type 
TP53 gene. Furthermore, many studies indicate that the p53 signal transduction 
pathway is intrinsically intact in neuroblastoma (10, 11, and 12), suggesting that 
circumvention of the p53 barrier in this tumor entity relies primarily on an inappropriately 
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increased activity of inhibitors of p53 signaling or, alternatively, on a loss of positive 
regulators of p53 activity. 
Aberrant cytoplasmic localization of wild-type p53 has been proposed as one of 
the mechanisms for p53 inactivation in neuroblastoma cells. Although controversy exists 
on the frequency and functional relevance of this phenomenon, it has been extensively 
documented that cytoplasmic p53 sequestration does occur in at least some cases of 
neuroblastoma. Interestingly, as will be discussed below, cumulating evidence indicates 
that an increased activity of MDM2 or a dysfunction of its functional counterpart HAUSP, 
a principal p53-deubiquitinating enzyme, lies at the molecular basis of cytoplasmic p53 
retention in neuroblastoma, further underscoring the importance of MDM2 deregulation 
as a means to escape from p53 control.  
An initial study found cytoplasmic p53 sequestration in 96% of undifferentiated 
neuroblastoma tumors; whereas this phenotype was absent in differentiated 
neuroblastoma tumors (13). However, other studies have reported a predominant 
nuclear localization of p53 in undifferentiated neuroblastoma tumors, and both 
cytoplasmic and nuclear p53 in differentiating neuroblastoma (14, 15, and 16). 
 Conflicting results also exist for neuroblastoma cell lines, as the subcellular 
localization of p53 has been reported to be exclusively cytoplasmic (e.g. in IMR-32 and 
SK-N-SH cells), primarily cytoplasmic and weakly nuclear (e.g. in IMR-32 and SK-N-SH 
cells), equally cytoplasmic and nuclear (e.g. in SK-N-SH cells), predominantly nuclear 
(e.g. in IMR-32 cells), and completely nuclear (e.g. in IMR-32 and SK-N-SH cells). Some 
of the discrepancies may be explained by cross-reactivity of the antibodies used to 
detect p53 and by different methods of tissue fixation and cell preparation. Nonetheless, 
it is generally accepted that some cytoplasmic p53 does exist in neuroblastoma, 
although the prevalence and importance of cytoplasmic p53 sequestration remain a 
subject of debate. It has been reported that abnormal cytoplasmic p53 localization may 
attenuate the DNA damage–induced G1 checkpoint function and the apoptotic activity 
(17, 18) of wild type p53 in some neuroblastoma cells. On the contrary, many studies 
have shown that the DNA-binding and transactivation capacity of p53 and the p53 signal 
transduction pathway are intact in neuroblastoma cells with wild-type p53 (9, 10, and 
11),  indicating that cytoplasmic retention of wild-type p53 is either an infrequent 
anomaly or a relative block on p53 that can be overcome by appropriate p53-inducing 
stimuli. Proposed mechanisms for abnormal p53 accumulation in the cytoplasm of 
neuroblastoma cells include hyperactive nuclear export of p53, cytoplasmic tethering of 
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p53, resistance of p53 to proteasomal degradation, and possibly impaired nuclear re-
import of p53. A unifying theme common to these diverse mechanisms may be the 
involvement of a disrupted MDM2/HAUSP regulation of p53. It has been firmly 
established that cytoplasmic p53 sequestration in neuroblastoma cells is at least in part 
caused by enhanced nuclear export and that MDM2 plays an important role in this 
nuclear exclusion of p53. Once transported to the cytoplasm, p53 may be held in this 
compartment by a cytoplasmic anchor protein, such as Parc (19). A comparable 
cytoplasmic anchoring function may be exerted by the large T antigen from human 
polyomavirus BK (20), by the glucocorticoid receptor (21), and by the MDM2-related 
protein MDM4 (also known as MDMX) (22). It has also been shown that p53 in 
neuroblastoma cells is aberrantly ubiquitinated because of an impaired interaction 
between p53 and the deubiquitinating enzyme HAUSP, and that this hyperubiquitination 
contributes to cytoplasmic p53 sequestration (23). In keeping with the deregulation of 
MDM2/HAUSP, interference with p53 hyperubiquitination by targeted inhibition of the 
p53–MDM2 interaction in neuroblastoma cells has been shown to relocate p53 from the 
cytoplasm to the nucleus and to restore the transcriptional and apoptotic activities of p53 
(23). 
The rarity of TP53 mutations in neuroblastoma has been a puzzling issue to 
many investigators given the potent antitumor capacity of wild-type p53 protein. A 
substantial number of alternative p53-inactivating lesions have been identified in 
neuroblastoma during the past few years, many of which interfere with proper 
functioning of the p14ARF-MDM2- p53 axis. Full characterization of the nature and 
relative importance of the different blocks on the p53 pathway in neuroblastoma cells 
awaits genome-wide experimental approaches in well-controlled model systems.  
 
 
The p14ARF-MDM2-p53 Axis and Lesions at the MDM2 and CDKN2A 
(p16INK4a/p14ARF) Loci in Neuroblastoma 
 
The MDM2 oncoprotein, a human homolog of the ‘mouse double minute 2’ gene 
product that was originally identified in a spontaneously transformed mouse cell line with 
double minute chromosomes (24), is a critical negative regulator of p53 stability and 
activity. It has been well established that p53 and MDM2 mutually control their cellular 
levels and form a tight auto regulatory feedback loop (Figure 1a). Under normal 
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physiological conditions, p53 protein levels are very low because of MDM2-dependent 
proteasomal degradation. Exposure of cells to harmful stimuli, such as DNA damage, 
hypoxia, telomere erosion, ribonucleotide depletion, or oncogene activation, results in a 
number of modifications on the p53 protein (e.g. phosphorylation and acetylation), which 
suppress the binding of p53 to MDM2 and which lead to accumulation and increased 
transcriptional activity of p53 (25). In addition to inducing expression of target genes 
involved in cell-cycle arrest, DNA damage repair, senescence, and apoptosis, p53 also 
transactivates the MDM2 gene (Figure 1b). The resulting increase in MDM2 expression 
limits the duration and intensity of a non-lethal stress response. There are several 
mechanisms by which MDM2 is capable of counteracting p53 activity and stability 
(Figure 1c). First, MDM2 binds to the transactivation domain of p53 and, therefore, 
directly interferes with recruitment of the basal transcriptional machinery and 
transcriptional coactivators (26, 27, and 28). Second, MDM2 acts as an E3 ubiquitin 
ligase for p53 in a dosage-dependent manner. Low levels of MDM2 promote p53 
monoubiquitination, which may both stimulate nucleocytoplasmic shuttling of p53 
because of unmasking of a nuclear export signal and decrease p53 transactivation 
capacity owing to unavailability of the ubiquitinated lysine residues for acetylation. At 
higher levels, the activity of MDM2 results in polyubiquitination and subsequent 
proteasomal degradation of p53 (29, 30). Third, MDM2 also induces monoubiquitination 
of histone proteins in the vicinity of p53-responsive promoters, resulting in transcriptional 
repression (31). Fourth, MDM2 has been reported to inhibit p53 transcriptional activity by 
promoting conjugation of the ubiquitin-like protein NEDD8 to p53 (32). Fifth, MDM2 may 
also contribute to p53 inactivation by recruiting several corepressor proteins, such as 
HDAC1, CTBP2, YY1 and KAP1 (33-36). 
A central negative regulator of MDM2 is the tumor suppressor protein p14ARF, 
which is an alternate reading frame product of the CDKN2A locus on chromosome 9p21. 
This locus encodes two structurally unrelated growth-inhibitory proteins, p16INK4a and 
p14ARF, that govern the activities of the pRb and p53 tumor suppressor pathways, 
respectively. The p14ARF protein serves as a key sensor of hyperproliferative signals 
generated by activated oncogenes and engages both p53-dependent and p53-
independent pathways to protect cells from malignant transformation (37, 38). 
The importance of p14ARF-mediated signaling of oncogene activity in the p53 
tumor surveillance network is underscored by observations in mice models that the 
cancer-protective activity of p53 is abolished in the absence of the murine homolog 
10 
 
p19ARF (39, 40). The physical interaction between p14ARF and MDM2 is in large part 
responsible for the ability of p14ARF to stabilize and activate p53. P14ARF prevents 
MDM2 from targeting p53 for degradation by inhibiting the E3 ubiquitin ligase activity of 
MDM2 (41) and by blocking nuclear export of MDM2 and p53 (42, 43).  It has also been 
established that p14ARF, which is predominantly a nucleolar protein, is capable of 
mobilizing MDM2 into the nucleolus, and it has, therefore, been proposed that p14ARF 
releases nucleoplasmic p53 from the inhibitory grip of MDM2 by inducing nucleolar 
sequestration of MDM2 (44).  
Not surprisingly, many forms of cancer develop defects in MDM2 or p14ARF to 
escape from p53 control. Genetic aberrations of the MDM2 locus as well as genetic or 
epigenetic disruption of the CDKN2A (p16INK4a/p14ARF) locus may account for 
inactivation of the p53 pathway in a subset of neuroblastoma tumors, mainly at relapse. 
Amplification of chromosome 12q–derived sequences encompassing the MDM2 gene 
has been described almost exclusively in neuroblastoma tumors and cell lines that 
simultaneously have amplification of the MYCN oncogene on chromosome 2p24, and is 
associated with attenuated p53 transcriptional function and multidrug resistance (45, 46).  
The CDKN2A (p16INK4a/ p14ARF) locus at 9p21 is the most frequent target of 
homozygous deletion in both neuroblastoma cell lines and primary tumors, and has been 
found to be silenced by methylation in several neuroblastoma cell lines (47,48, and 49). 
It has been estimated that approximately half of all neuroblastoma cell lines established 
at relapse are subject to a genetic or epigenetic lesion of the MDM2 or CDKN2A 
(p16INK4a/p14ARF) locus, but these findings await confirmation in a study that takes 
also neuroblastoma tumor samples into account (50). A recent line of evidence 
supporting a role for MDM2 activity in the development and malignant behavior of 
neuroblastoma stems from epidemiological studies of a T4G single nucleotide 
polymorphism in the MDM2 promoter (SNP309; rs2279744). The presence of this 
polymorphism increases the affinity of the MDM2 promoter for a transcriptional activator, 
Sp1. This results in enhanced transcription of MDM2, overexpression of the MDM2 
protein, attenuation of the p53 pathway, and may eventually lead to accelerated tumor 
formation. Both individuals homozygous for SNP309 (G/G) and subjects heterozygous 
for SNP309 (T/G) have an increased risk for the development of neuroblastoma, and 
neuroblastoma patients carrying the SNP309 variant (G/G or T/G) present with a more 
advanced clinical stage and have a shorter 5-year overall survival than patients 
homozygous for the wild-type allele (T/T) (51, 52). 
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These findings suggest that an increased activity of MDM2 due to the presence 
of SNP309 has an adverse effect on the development, aggressiveness, and outcome of 
neuroblastoma, and provide a direct incentive for the development of novel therapeutic 
strategies aimed at MDM2 inhibition. 
 
Transactivation of MDM2 Expression by MYCN 
 
Amplification of the MYCN oncogene plays a central role in the pathophysiology 
and clinical behavior of high-risk neuroblastoma. This genetic aberration is found in 
approximately 22% of all neuroblastoma tumors and is highly correlated with advanced 
stages of disease, rapid progression, treatment failure, and fatal outcome (53, 54). 
MYCN amplification results in overexpression of the MYCN protein, which is a bHLH 
transcription factor that operates in a heterodimeric complex with Max family proteins to 
promote cell growth and proliferation (55). The oncogenic effects of MYCN 
overexpression have been established in a variety of model systems. Enhanced 
expression of MYCN elicits neoplastic transformation of mammalian cells, induces 
autocrine growth factor activity and increases proliferative potential, accelerates cell-
cycle progression, enhances tumor cell motility and invasiveness, evokes genomic 
instability through disruption of the regulation of centrosome replication, diminishes 
expression of angiogenesis inhibitors, and promotes immune escape in neuroblastoma 
by inhibiting the chemoattraction of natural killer T cells (56, 65). 
Direct evidence for a causative role of MYCN amplification in the pathogenesis of 
neuroblastoma is derived from the observation that transgenic mice with targeted 
expression of MYCN in normal neuroblasts develop tumors with a phenotype very 
similar to human neuroblastoma (66). Importantly, the mouse model of neuroblastoma 
faithfully recapitulates the p53 wild-type status, chemosensitivity, and p53-dependent 
apoptotic responses of human neuroblastoma. 
However, aberrant MYCN expression also potently sensitizes neuroblastoma 
cells to drug- and stress-induced apoptosis, and, therefore, needs to be accompanied by 
a collateral impairment of the cell death program to provide a selective advantage for the 
tumor. This counterbalance to the intrinsic apoptosis-sensitizing effect of MYCN may be 
delivered by an increased activity of MDM2. The study conducted in our laboratory with   
a ChIP cloning approach combined with oligonucleotide pull-down and luciferase 
reporter assays has successfully identified MDM2 as a direct transcriptional target of 
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MYCN in neuroblastoma cells (67). In this study, endogenous MDM2 mRNA and MDM2 
protein levels were rapidly upregulated on induction of MYCN in MYCN-conditional 
neuroblastoma cell lines, whereas targeted inhibition of MYCN in MYCN-amplified 
neuroblastoma cells resulted in reduced MDM2 levels with stabilization of p53 and 
induction of apoptosis.  
These data suggest that MYCN driven expression of MDM2 may constitutively 
debilitate the p53 pathway in MYCN-amplified neuroblastoma cells, providing both a 
possible mechanism for evasion of MYCN-primed apoptosis and an explanation for the 
low frequency of TP53 mutations in these cells. This view is further strengthened by 
evidence that the closely related MYC (c-MYC) oncoprotein also relies on MDM2 to 
restrain p53-mediated apoptosis, as Myc-induced lymphomagenesis in mice is 
profoundly suppressed by haploinsufficiency of Mdm2 because of a drastic increase in 
p53-dependent apoptosis (68). 
Based on the central role of MYC oncogenes in neuroblastoma tumorigenesis 
and the necessity of inhibiting wild-type p53 activity to prevent apoptosis, our laboratory 
hypothesized that MDM2-mediated suppression of p53 is a vital component of MYCN-
driven tumor initiation and progression. 
To test this hypothesis, we crossed the well-characterized pTHMYCN transgenic 
model of neuroblastoma and the Mdm2 haploinsufficient mouse model (69) and 
compared tumor latency and incidence in the resulting animals. We found that 
Mdm2+/−MYCN+/+ transgenics had markedly delayed tumor development and had a 
lower overall incidence of tumors, strongly implicating Mdm2-mediated blockade of p53 
as an essential step in the pathogenesis of neuroblastoma. Analysis of the resulting 
tumors demonstrated high levels of p53 and dramatically decreased levels of Arf. We 
further confirmed the impact of MDM2 levels on neuroblastoma growth in xenograft 
models using conditional short hairpin RNA (shRNA)–mediated knockdown of MDM2. 
Based on our data, we propose that both MYCN-mediated activation of MDM2 and 
suppression of ARF contribute directly to the pathogenesis of neuroblastoma. Further 
work designing molecular targeted therapies that modulate these pathways should 
provide clinically effective novel therapeutic approaches for neuroblastoma. 
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MDM2 Inhibition in Neuroblastoma 
The search for specific small molecule inhibitors of MDM2 is an active area of 
research. Recently, Lyubomir T. Vassilev and his group at Hoffman-La Roche 
characterized a group of cis-imadazoline analogues (termed Nutlins) that displace p53 
from its binding pocket in the N-terminus of MDM2. These compounds have active (a) 
and inactive (b), enantiomer forms. Nutlin-3a binds with 150-fold higher affinity than does 
Nutlin-3b.  
The outcome of p53 activation in cells ranges from a reversible cell-cycle arrest 
and induction of DNA repair to more drastic responses, such as cell death by apoptosis 
or senescence. p53 transactivates genes that induce apoptosis, such as FAS, BBC3 
(PUMA), PMAIP1 (Noxa), and BAX, as well as genes that induce cell-cycle arrest, such 
as CDKN1A (p21) and GADD45. The choice of biological response to p53—death or 
survival— is strongly influenced by the presence of death or survival signals, and such 
signals act both upstream and downstream of p53. However, the exact molecular 
mechanism by which the switch between arrest and apoptosis is implemented remains 
largely unknown. 
In a recent study, Nutlin-3a was shown to have potent in vitro and in vivo effects 
against tumor cells with wild-type p53 (70). As neuroblastoma tumors are universally p53 
wild type at diagnosis, we sought to characterize the effects of Nutlin-3a on 
neuroblastoma cells. To test our hypothesis that altered p53 stabilization contributes to 
the robust response of neuroblastoma to MDM2 inhibition, we monitored the kinetics of 
apoptosis in response to Nutlin 3a and evaluated the levels of p53 at early time points 
after treatment. We found that p53 levels responded to Nutlin in neuroblastoma with a 
time course quite distinct from the pattern of comparable solid tumor cell lines and 
previously published studies. 
We demonstrate here a very rapid stabilization of p53 in response to MDM2 
inhibition in neuroblastoma cells associated with rapid apoptotic response. Additionally, 
MDM2 inhibition combined with etoposide induce a robust apoptotic response in 
neuroblastoma cell lines and primary tumor cultures. As expected these results are 
specific for the active –3a enantiomer and confirmed that the effects seen on 
proliferation and apoptosis were due to p53 dependent effects of MDM2 inhibition. We 
believe that MDM2 inhibition dramatically enhances the activity of genotoxic drugs in 
neuroblastoma and should be considered as an adjuvant to chemotherapy for this 
aggressive pediatric cancer and for possibly other p53 wild-type solid tumors. 
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P53 and Metabolism- Efficient combination of MDM2 and mTOR inhibition 
 
It has almost become a truism to say that cancer cells have acquired distinctive 
characteristics that distinguish them from their normal counterparts, but it is important 
remembering that among the very first of these differences to be recognized were the 
changes in tumour cell. The importance of metabolism in cancer has revived enthusiasm 
for the study of how these pathways are controlled, revealing some interesting 
contributions from well-known oncoproteins and tumour suppressor proteins. Among 
these is p53, which is now also emerging as an important player in the response to and 
the regulation of metabolic stress. 
Compared with our understanding of the functions of p53 in controlling cell cycle 
progression and apoptosis, this is a new and burgeoning area of influence for p53, with 
some confusing and apparently contradictory results highlighting gaps in our 
understanding. However, these activities of p53 are indisputably interesting and probably 
extremely important. Furthermore, it is clear that the role of p53 in responding to and 
effecting alterations in metabolism will have consequences beyond cancer, influencing 
various other aspects of disease and normal life (Table 1). 
Metabolic pathways in normal cells are tightly regulated to allow cell growth or 
survival, depending on the conditions. Nutrient availability supports the synthesis of 
proteins, lipids and nucleic acids for cell growth and proliferation, whereas starvation 
triggers a series of responses to restrict cell proliferation, maximize energy production 
(by switching to the breakdown rather than the synthesis of macromolecules) and help 
cell survival.  
One important node in these responses is mTOR, which promotes protein 
synthesis and suppresses the induction of autophagy (a mechanism that can mobilize 
alternative energy sources and is discussed in more detail below). Key regulators of 
mTOR are AKT, which is stimulated by growth factors to activate mTOR, and AMP-
activated protein kinase (AMPK), which responds to an increased AMP/ATP ratio under 
conditions of low energy to repress mTOR. These growth regulatory cascades intersect 
with the metabolic pathways that control energy production and biosynthesis, in which 
AKT can promote the anabolic, energy-consuming pathways (such as fatty acid 
synthesis) that are necessary for cell growth and AMPK drives the catabolic, energy-
producing responses that are needed under conditions of metabolic stress. Layered over 
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this complexity are the pathways that regulate cell division and survival; virtually all parts 
of this intricate network can be profoundly perturbed in cancer cells. 
The mammalian TOR protein (mTOR) forms two distinct signaling complexes, 
called mTORC1 and mTORC2. The mTORC1 complex, which, in addition to mTOR, 
consists of raptor, PRAS40, and mLST8, is responsible for control of cell growth and 
protein synthesis (71). 
Genotoxic stress was suggested to inhibit mTORC1 activity through p53-
dependent upregulation of negative regulators such as PTEN, TSC2, and AMPKb1 (72). 
p53 also increases the phosphorylation of the AMPKa subunit, leading to AMPK 
activation. However, the precise physiological mechanism by which p53 activates AMPK 
and inhibits mTOR was not established. 
In our attempt to identify additional pathways to potentiate the p53 response, we 
use oligonucleotide microarray analysis to explore the molecular mechanism of the 
Nutlin-induced p53 biological response. Two p53 target genes genes, Sestrin1 
(Sesn1)/PA26 and Sestrin2 (Sesn2)/Hi95, were significantly affected by Nultin treatment. 
Previous studies have shown that Sesn1 and Sesn2, whose expression is 
induced upon DNA damage and oxidative stress, may have a cytoprotective function 
based on regeneration of overoxidized peroxiredoxins (73). Recently has been also 
demonstrated that Sesn1 and Sesn2 are negative regulators of mTOR signaling and that 
they execute this redox-independent function through activation of AMPK and TSC2 
phosphorylation. The important study of Budanov et al (74), provide in vivo evidence for 
the functional importance of Sesn2 in inhibition of mTOR signaling in mice treated with a 
p53-activating alkylating agent. Hence, Sesn1 and Sesn2 link genotoxic stress, p53, and 
mTOR signaling. 
Mammalian target of rapamycin (mTOR) signaling pathway is active in 
neuroblastoma and mTOR inhibition has demonstrated antiproliferative effects in vitro 
and in vivo in aggressive MYCN amplified neuroblastoma. In addition, signaling through 
mTOR is elevated in neuroblastoma tumor-initiating cells (TICs) and mTOR can increase 
hypoxia-inducible factor (HIF) translation. 
For this reason we investigated the role of Sestrin1 and Sestrin2 in p53-mediated 
apoptosis in neuroblastoma and the interaction of mTOR and p53 pathways after their 
simultaneous blockade using the mTOR inhibitor, Temsirolimus and the MDM2 inhibitor, 
Nutlin 3a. 
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2. MATERIALS AND METHODS 
 
Mice Breeding 
 
Mice were handled in accordance with an approved protocol from the Animal 
Research Committee of Baylor College of Medicine. Mdm2+/− mice (C57b strain; Dr. 
Lozano, MD Anderson Cancer Center) were first backcrossed for seven generations with 
wild-type 129/Svj mice to gainMDM2 heterozygousmice with 129/Svj strain 
(Mdm2+/−MYC−/−). 
The neuroblastoma model is highly strain-dependent, and to ensure equivalent 
comparisons, Mdm2+/− and Mdm2+/+ mice were all derived from the same founding 
mice and littermates used for all analyses. For genotyping PCR, tail DNA was prepared 
using DNeasy kit and genotyping for MDM2 performed as previously published (69). 
MYCNheterozygosity or homozygosity was confirmed by quantitative PCR (qPCR) for 
the human pTH-MYCN transgene using the following primers. 
 
 
Implantation of Neuroblastoma Xenograft 
 
Five million ZC21 or SJ9 cells were resuspended together with 100 µl of Matrigel 
and injected subcutaneously in 4-week-old severe combined immunodeficient (SCID) 
mice with mixed gender. One week after injection, mice were separated into two groups 
that were fed with drinking water either containing 2 mg/ml of doxycycline or not. Fresh 
water with or without doxycycline was served to the mice once every 2 days until the 
experiments were complete. The sizes of tumors in each mouse were measured daily 
starting from 10 days after cell injection. The data were plotted using Kaplan-Meier 
method to analyze the tumor growth. 
 
 
In vivo xenografts and administration of mTOR inhibitor 
 
One million SY5Y were orthotopically injected in 4-week-old nude mice. Tumors 
were measured daily with a digital caliper and tumor volume calculated as length x 
width2 x0.44. At a tumor volume of > 0.2 ml the animals were randomized to receive 
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either Temsirolimus, CCI-779, (20 mgkg) intraperitoneally daily for 12 days or no 
treatment (controls). Tumor materials were fixed in 4% paraformaldehyde and frozen in 
liquid nitrogen and stored at 4 or -80 C respectively. 
 
Cell Lines and Cell Culture 
 
The ZC21 and SJ9 conditional subclones were generated from human 
neuroblastoma cells IMR32 (American Type Culture Collection, Manassas, VA) or SJ3-
12 (a gift from Dr. Dirk Geerts, University of Amsterdam, the Netherlands) by 
transfection with pSuperior plasmids containing 64-bp shRNA hairpin loop constructs 
cloned into its unique Bgl II and HindIII sites. The MDM2 messenger RNA (mRNA) 
sequence targeted with small interfering RNA (siRNA) was gccattgcttttgaagtta. The 
expression of shRNA is driven by an inducible (Tet-ON) H1 promoter, which is activated 
by the presence of doxycycline. After transfection, cells were grown under puromycin 
selection for 2 weeks. Single clones were isolated, expanded, and characterized for their 
cellular MDM2 levels 72 hours after doxycycline treatment. Cell lines ZC21 and SJ9, 
showing remarkably decreased level of MDM2 as determined by Western blot, were 
used for the xenograft study. 
The JF, IMR32, HCT 116, MCF7 lines were maintained in RPMI 1640, MEMa, 
McCoy’s 5A, DMEM plus 1% insulin respectively, supplemented with 10% fetal bovine 
serum and 1% penicillin and streptomycin. The SJSA-1 cells were grown in RPMI 1640 
medium supplemented with 10mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 
g/L sodium bicarbonate, 10% fetal bovine serum and 1% penicillin and streptomycin. All 
three primary neuroblastoma lines (p202, p218, pH) were grown in IMDM, supplemented 
with 20% fetal bovine serum, 0.1% ITS (bovine insulin, human transferrin and sodium 
selenite) and 1% penicillin and streptomycin. The p53-mutant cell line SJ3-12 (21 
amminoacids deletion in the DNA binding domain) was provided by Ham Geertz and 
used as control. Nutlin 3a was provided by Dr. Vassilev (Roche, Nutley, NJ). 
 
Western Blot 
 
Antibodies used are as follows: a-p53, a-MDM2, p21, a-actin monoclonal 
antibodies and horseradish peroxidase –conjugated goat a-mouse antibody were used 
for Western blot analysis as described below. Cells were directly lysed with H-1 lyses 
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buffer (50 mM HEPES, 250 mM NaCl, 0.5% NP-40) for 20 minutes on ice and proteins 
were quantified by Bradford assay before electrophoresis. Actin was used for loading 
control in all experiments. Cycloheximide (CHX) (25 ug/ml) (Sigma) was used as protein 
synthesis inhibitor and added to the cells for the duration of Nutlin A treatment. 
 
Terminal Deoxynucleotidyl Transferase Apoptosis Assay 
 
IMR32, JF, p218, p202, pH, HCT 116 +/+ and +/-, MCF7, SJSA cells were plated 
in 10-cm dishes at 2 million cells per dish. The cells were then exposed to Nutlin A for 
16, 24, and 48 hours. Briefly, cells were harvested in PBS and incubated in 3 mL of 1% 
formaldehyde-PBS for 15 minutes on ice. The cells were then fixed in 70% ethanol-PBS 
overnight at – 20 C.  50uL of the terminal deoxynucleotidyl transferase (TdT) reaction 
mix were added to each sample consisting of 10uL of 5 X reaction buffer, 1.5uL TdT, 
5uL CoCl2, 0.5uL biotin-16-dUTP and 33uL dH2O. The samples were incubated for 1 
hour at 37C and then washed with PBS. For fluorescence-activated cell sorting analysis, 
100uL avidin FITC buffer was then added to each sample. The samples were incubated 
in the dark at room temperature for 30 minutes and washed in 1X PBS + 0.1% Triton X-
100. Fluorescence-activated cell sorting analysis was done using CellQuestPro and 
standard software. All the experiments were done in triplicate. 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay 
 
Briefly, 0.5 x 105 cells/mL were plated into 96-well microtiter plates, incubated at 
37 C, and cultured overnight. Stock solutions of Nutlin 3a or 3b in DMSO were diluted in 
PBS and added to the appropriate concentration by serial dilutions. PBS alone, medium 
alone, and medium plus DMSO were control wells for each dilution. Plates were 
incubated for 72 hours and then centrifuged for 5 minutes at 1,000 rpm. Half the medium 
(135 uL) was removed and replaced with fresh medium. Then, 15 uL MTT were added to 
each well. Plates were shaken in the dark for 5 minutes, incubated for an additional 4 
hours, and read at 550 nm in the plate reader. 
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Real-time quantitative PCR 
 
SY5Y and IMR32 cells were treated with 5 or 10 uM of Nutlin-3a for up to 8 
hours. RNA was prepared from cells using a RNeasy Mini Kit (Qiagen, Valencia, CA, 
USA), and first-strand cDNA was generated using random hexamers (SuperScript III 
First-Strand Synthesis SuperMix) from 1 mg total RNA. The mRNA expression levels of 
p53 and 18S were quantified using TaqMan gene expression assays. 
 
Quantitation of intracellular proteins by flow cytometry  
 
For intracellular phospho S6 detection, cells were fixed with 2% 
paraformaldehyde, permeabilized with 100% ice-cold methanol and incubated for 1 h at 
4 C with antibody against phosphoS6 Alexa Fluor 647 or its isotypic control, according to 
the manufacturer’s instructions. 
 
Oligonucleotide Microarray Data Analysis 
 
P202 cells were exposed to the treatment with Nutlin 3a or the inactive 
enantiomer Nutlin 3b for 8, 16 and 24 hours. Biological duplicates of the experiment 
were performed. We hybridized cDNA prepared from p202 cells untreated or treated with 
10 uM of Nutlin 3a at different time points to Affymetrix hgu133a chips containing 
approximately 22,000 probe sets mapping to 15,000 known human genes. 
Raw data from the hgu133a2 chips were normalized using the robust multiarray 
average with GC correction (GCRMA) procedure, implemented in the R package gcrma 
(quantile-based normalization with background correction based on gene chip content of 
probes). Per gene hypothesis testing was performed using the significance analysis of 
microarrays (SAM) procedure, implemented in the R package siggenes, using linear 
models for microarray data. Pathway analysis was performed using a modified version of 
the procedure in Tian et al. (75). 
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3. RESULTS 
 
Mdm2 Deficiency Extends the Tumor Latency and Decreases Incidence in MYCN 
Transgenic Mice 
 
To investigate the role of Mdm2 in neuroblastoma pathogenesis in vivo, we 
generated MYCN+/+ transgenic mice (carrying two copies of the targeted transgene) 
with either wild-type Mdm2+/+ or a heterozygous knockout Mdm2+/−. The strategy for 
animal breeding is shown in Figure 2a. In pTH-MYCN transgenics, the human MYCN 
gene is driven by the tyrosine hydroxylase promoter, which is active in migrating cells of 
neural crest during early development and in the resulting peripheral sympathetic 
nervous tissue from which neuroblastoma arises (76). pTH-MYCN transgenic mouse 
(MYCN+/+,129/Svj strain) spontaneously develops neuroblastoma in a MYCN dose-
dependent manner (77, 78). Both cohorts contain two copies of human MYCN gene, 
express elevated levels of MYCN in neural crest precursors and developing sympathetic 
ganglia, and are expected to develop tumors efficiently, permitting us to study the role of 
Mdm2 on MYCN-driven tumors by comparing the two cohorts. Consistent with previous 
studies (69, 78), we found no difference in animal weights, activity, oral intake, or fertility 
between cohorts. As expected, both Mdm2+/+ and Mdm2+/− mice developed large 
abdominal neuroblastomas. Tumors from both groups had an aggressive 
undifferentiated phenotype with indistinguishable histologic diagnosis, morphology, and 
fine structure containing neurosecretory granules (Figure 2 b and c). 
Overall, 110 Mdm2+/− and 117 Mdm2+/+ mice were observed for up to 1 year. 
Because no mice died of tumors after 110 days, we present Kaplan-Meier survival 
analysis taken out to 200 days (Figure 3). Mice were monitored at least twice a week for 
tumor formation and changes in health status. Mice were killed within 10 days of the 
detection of tumors to be examined in accordance with our institutional review board–
approved animal protocol. Figure 3a illustrates the statistically significant differences in 
cumulative survival probabilities between Mdm2+/− and Mdm2+/+ mice (as analyzed by 
Mantel-Cox and Wilcoxon methods). We found a dramatic difference in the median 
survival time (defined as time of sacrifice), which is closely correlated with tumor latency 
because these tumors, once fully established, are rapidly fatal. For Mdm2+/+ mice, 
median latency was 55 days (95% confidence intervals [CI], 52-57 days), and for 
Mdm2+/− mice, tumor latency was 74 days (95% CI, 72-81 days; P < .001). Thus, the 
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mean time to tumor onset was delayed approximately 20 days (38%) in the Mdm2 
haploinsufficient mice, supporting our contention that Mdm2-mediated suppression of 
p53 is a rate-limiting step in MYCN-driven neuroblastoma tumorigenesis. 
Overall, the MYCN transgenic mice wild type for Mdm2 had a very high incidence 
of tumors with 94% (110/117) of mice developing tumors, in line with previously 
published studies of the pTHMYCN tumor model in the Svj-129 background (79). 
However, the Mdm2 haploinsufficient mice had a significantly lower incidence of 80% 
overall (88/110 total; P < .001). This difference was sex dependent (Figure 3b and 3c). 
Seventy-six percent of female Mdm2+/− mice (47/62 animals) developed tumors 
compared with 93% (55/ 58 animals) of female Mdm2 wild-type mice (P < .001). For 
male mice, Mdm2 haploinsufficiency had an insignificant influence on overall tumor 
incidence, with 89% (43/48 animals) of the Mdm2+/− mice compared with 95% (55/59 
animals) of the Mdm2 wild-type mice developing tumors (P value not significant). Further 
analysis of tumor latency according to sex revealed a trend toward increased latency in 
the male Mdm2+/− mice compared with the female Mdm2+/−, but this was not significant 
by Cox regression analysis. No sex-dependent difference in latency or incidence was 
seen in the Mdm2 wild-type pTH-MYCN mice.  
The significant decrease in tumorigenesis in the female Mdm2-deficient mice 
may be secondary to interaction between MDM2 and the estrogen-dependent signaling 
in these mice. 
Because a major role of MDM2 is inhibition of p53 activity, it is possible that the 
delay to tumor formation and the reduced incidence reflect the need for additional 
genetic events to overcome increased p53-mediated tumor suppression. Since 
decreased Mdm2 and increased baseline p53 levels could lead to selective pressure to 
mutate p53 during tumorigenesis, we analyzed the sequences of p53 complementary 
DNA in a representative sample of tumors. Sequence data from 15 Mdm2+/− and 8 
Mdm2+/+ tumors revealed only wild-type p53, consistent with the almost complete 
absence of p53 mutations found in primary human neuroblastomas. 
 
Mdm2 Deficiency Alters p53 Regulation and Activity in Neuroblastoma 
 
The data shown in the previous section suggest that Mdm2 is critical for the 
development of MYCN-driven tumors and that a 50% decrease in Mdm2 significantly 
alters tumorigenesis. In cultured neuroblastoma cells, siRNA-mediated knockdown of 
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MDM2 leads to a significant increase of p53 and sensitization to apoptotic stress. To 
better understand the regulation of p53 and related proteins in Mdm2+/− and Mdm2+/+ 
tumors, we performed semiquantitative Western blot and qRT-PCR analysis of Mdm2, 
p53, p21, Mdm4, p19Arf, and MYCN in 12 tumors from each cohort, as shown in Figure 
4 . As expected, Mdm2 mRNA and protein levels are reduced to approximately 50% of 
wild type in the Mdm2 haploinsufficient mice. Western blots demonstrate that p53 protein 
levels are remarkably higher in Mdm2+/− tumors, whereas the mRNA levels do not 
differ. This is consistent with decreased Mdm2-mediated ubiquitination of p53 and 
relative stabilization of the protein compared with Mdm2+/+ tumors.  
A primary transcriptional target of p53 is p21CIP1/WAF1, which encodes the 
cyclin-dependent kinase inhibitor, p21, a central cell cycle regulator. Consistent with 
observations of increased p53 protein and presumably its transcriptional activities, the 
average p21 mRNA in Mdm2+/− tumors was approximately 80% higher than that in 
Mdm2+/+. However, a trend toward decreased p21 protein levels is observed in 
Mdm2+/− tumors, suggesting that p21 protein is destabilized in these tumors. 
Interestingly, it has been shown that Mdm2 can inhibit p21 by promoting its ubiquitin-
dependent and –independent proteosomal degradation (80, 81). However, decreased 
p21 protein levels would not be expected to correlate with decreased Mdm2 levels in 
Mdm2+/− mice, and an alternative mechanism for p21 protein reduction is likely invoked 
in this cohort. 
We also analyzed levels of Mdm4 (MdmX), a homolog of Mdm2 with overlapping 
and distinct regulatory effects on p53 (82). Mdm4 has potent cell cycle effects 
independent of Mdm2 (83) and he binding of Mdm4 to p53 at its N-terminal domain 
suppresses its transactivation activity.  Although a trend toward decreased levels of 
Mdm4 can be seen, no significant change in Mdm4 protein or mRNA levels were 
detected. This suggests that Mdm4 levels do not compensate for low Mdm2 levels in 
Mdm2+/− tumors. 
In the data presented in this study, we provide the first in vivo evidence that 
MDM2 contributes to MYCN-driven tumorigenesis in neural crest–derived 
neuroblastoma with both Mdm2 haploinsufficient transgenic mice and human 
neuroblastoma xenografts in SCID mice using cell lines with shRNA-mediated 
conditional knockdown of MDM2. Both tumor latency and tumor incidence are 
significantly altered by the reduction in Mdm2 levels in the transgenic model. 
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We also demonstrate a strong influence of sex on tumor incidence in the Mdm2 
haploinsufficient mice with overall tumor rate, decreasing more than 18% in the female 
Mdm2+/− mice (P < .001). The estrogen receptor α (ERα) interacts with Mdm2 and p53 
and can inhibit Mdm2-mediated ubiquitination of p53. Subsequent increased p53 activity 
may be sufficient to further suppress tumorigenesis in female Mdm2 haploinsufficient 
mice. However, ERα may also act to increase Mdm2 levels indirectly and alter 
glucocorticoid receptor signaling, and Mdm2 can enhance ERα activity in breast cancer 
cells (84). It is also possible that p53-independent functions of Mdm2 or mouse strain–
specific effects account for the observed inhibition of tumorigenesis in the female mice. 
Neuroblastoma is almost exclusively found in premenarchal children, and clinical and 
mechanistic implications of these findings will require additional investigation. 
Both MYCN and MYCC activate apoptosis and stimulate proliferation 
simultaneously in culture cells. How the neural crest–derived precursors of 
neuroblastoma respond to aberrant MYC activation clearly depends on direct MYC 
transcriptional targets and on indirect and parallel oncogenic stimuli. Recent studies 
comparing the sympathetic ganglia of pTH-MYCN and wild-type mice have shown that 
MYCN expression leads to the persistence of proliferative rests of neuroblasts and that 
this correlates with tumorigenesis in a MYCN gene dose-responsive manner. The 
aberrant expression of MYCN likely disrupts apoptosis and differentiation favoring the 
proliferation of these “neuroblast” cells. We demonstrate that haploinsufficiency of Mdm2 
clearly prolongs tumor latency and decreases the incidence of tumor development in this 
same pTH-MYCN model. Lower levels of Mdm2 may weaken the oncogenic effect of 
MYCN in neuroblast precursors, increasing the requirement for additional genetic 
changes such as epigenetic silencing of ARF. 
 
MDM2 Inhibition Induces Rapid Apoptotic Response in Neuroblastoma Cell Lines 
And Primary Tumor Cultures  
 
We determined the ability of the 9-cell panel to undergo apoptosis after treatment 
with Nutlin-3a. Apoptosis induction was tested in five neuroblastoma lines (JF, IMR32) 
and primary tumor cultures (p202, p218, H) and four non-neuroblastoma human solid 
tumors including colorectal (HCT116), breast (MCF7) and osteosarcoma (SJSA-1). All 
cell lines have been reported to express wild type p53. 
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All proliferating cells were incubated with Nutlin 3A 10 uM for 24 and 48 hours 
and the TdT-positive fraction was measured by flow cytometry. At 24 hours all the 
neuroblastoma cell lines showed a significant percentage of apoptosis (range: 28-37%) 
compared with other solid tumor (range: 7-14%) (Figure 5a). 
At 48 hours, the overall apoptotic index in neuroblastoma cell lines did not 
change (range: 30-40%), except for the primary tumor cell line p218 (66%). A wide 
range of TdT positive cells was observed from as high as 69% (SJSA-1) to 10% (MCF7) 
in the non-neuroblastoma group at 48 hours. SJSA-1 line differs from the rest of the 
panel by the level of MDM2 expression; the gene is amplified 25 fold in this cell line, 
leading to correspondingly high expression of MDM2 protein. No differences in apoptotic 
response were noticed between the two lines HCT 116 wild type (HCT 116+/+) and null 
(HCT 116 -/-) at 24 and 48 hours (Figure 5b). 
The elevated levels of apoptosis, exclusive to neuroblastoma cell lines, prompted 
us to evaluate earlier time points. The apoptotic fraction was measured in selected 
neuroblastoma (p202) or non-neuroblastoma (MCM7, HCT 116+/+) cells after 12, 16, 
and 24 hours of treatment. A p53 mutant neuroblastoma line (SJ3-12), which lacks part 
of the DNA binding domain, was used as control. The results showed a significant 
increase in the apoptotic response in p202 line after 16 hours of treatment compared to 
non-neuroblastoma lines, where the apoptotic index overall does not change at 12,16, 
and 24 hours after treatment. No apoptotic effect was detected in the p53 mutant line at 
each time point (Figure 5c). 
Our data suggest that cancer cell lines can differ significantly in their kinetics of 
apoptotic response, possibly reflecting cells ability to undergo p53-dependent apoptosis, 
and neuroblastoma responds particularly rapidly to MDM2 inhibition. 
 
Nutlin 3A-mediated Apoptosis Occurs Through Rapid p53 Stabilization  
 
Next, we compare p53 stabilization in response to nutlin treatment in two 
neuroblastoma cell lines (IMR32 and the primary culture p202) and two non-
neuroblastoma lines (SJSA-1, osteosarcoma and HCT116, colon carcinoma). The cells 
were exposed to the treatment with Nutlin 3A for 2, 4, 8, 16, and 24 hours. Western blot 
analysis showed a very rapid increase in p53 level that was elevated to a similarly high 
level in both neuroblastoma lines after 2-4 hours exposure to Nutlin 3A, consistently with 
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our previously published data Barbieri et al (85). In contrast, in the other two solid tumor 
lines p53 levels began to increase at 8 hours after treatment (Figure 6). 
Surprisingly, p53 rapid stabilization in response to MDM2 inhibition is followed by 
equally rapid degradation in neuroblastoma lines, as shown by the dramatic decrease in 
p53 levels after 16 hours of treatment, that reach near the basal level after 24 hours. 
This modulation of p53 levels appears to be unique to neuroblastoma, as compared to 
the other tumor cell lines tested, where p53 stabilization gradual increase from 24 to 48 
hours after treatment.  
No significant effect in p53 stabilization was present in SJ3-12 after MDM2 
inhibition. The p53 target, p21, was tested in one selected neuroblastoma line (IMR32) 
and is significantly elevated 3 hours after Nutlin 3A addition, indicating p53 
transcriptional activity. 
The rapid p53 stabilization above a critical threshold in response to Nutlin A 
appears to trigger the rapid apoptosis induction of neuroblastoma cells. Moreover, the 
unique profile of p53 degradation, despite MDM2 inhibition, suggests that p53 in the cell 
lines tested may be degraded in an Mdm2-independent fashion. 
 
Nutlin 3a Potentiates the Antitumor Effects of Conventional Chemotherapeutic 
Agents in Neuroblastoma 
 
Next, we tested the effects of the combined treatment of Nutlin and cisplatin on 
cell growth viability and apoptosis to determine if inhibition of the p53-MDM2 interaction 
might potentiate the antitumor effect of conventional chemotherapy in neuroblastoma. 
Both N-type (neuronal) IMR32 and JF, and S-type (stromal) MYCN3, were 
simultaneously treated with increasing low dose of cisplatin and fixed low dose (2 
umol/L) of active or inactive enantiomer of Nutlin 3 for 72 hours. MTT analysis showed 
that treatment with Nutlin 3a plus cisplatin significantly reduced cell viability in all cell 
lines compared with treatment with cisplatin alone. The Nutlin 3b control showed no 
effect. The matched p53 wild-type HCT116+ and p53 null HCT116- cell lines were also 
tested to confirm the expected p53-dependent activity of Nutlin. Because MYCN 
expression can increase MDM2 expression, two MYCN-inducible cell lines, Tet21 and 
MYCN3, were tested to determine if changes in MYCN level altered the response to 
Nutlin. The IC50 did not change significantly upon MYCN induction, suggesting that the 
effect of Nutlin was sufficiently potent at these doses to overcome the 2- to 3-fold 
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increase in MDM2 seen upon MYCN induction in these cell lines. To assess the 
contribution of low dose of Nutlin 3a to apoptosis induced by chemotherapy, we did TdT 
assays after treatment with Nutlin 3a or Nutlin 3b plus chemotherapy. IMR32 cells were 
incubated with increasing doses of cisplatin or etoposide for 24 hours. TdT analysis 
shows that the addition of low-dose Nutlin 3a consistently increases apoptosis in 
combination with etoposide or cisplatin (Figure 7a). Thus, our data show that the 
addition of Nutlin 3a to chemotherapy both decreases cell viability as measured by MTT 
assay and increases sensitivity to apoptosis due to genotoxic chemotherapy. Because 
combined cisplatin and etoposide is commonly used for induction therapy in 
neuroblastoma, we further tested this combination plus Nutlin 3a. Although the addition 
of etoposide to cisplatin increased apoptosis at 24 hours, a dramatic increase was noted 
upon addition of Nutlin 3a. It should be emphasized that the doses of cisplatin and 
etoposide used in these studies induced minimal apoptosis as single agents (Figure 7b).  
 
Nutlin 3a Induces Profound Changes in Gene Expression Profiles Exclusively in a 
p53-Dependent Manner 
 
Our previous results demonstrated an efficient induction of apoptosis by Nutlin 3a 
in neuroblastoma cells expressing wild-type p53. To explore the molecular mechanism 
of action of Nutlin 3a in more detail, we conducted an oligonucleotide microarray 
experiment using a primary neuroblastoma line harboring wild-type p53, p202 (Figure 8).  
P202 cells were exposed to the treatment with Nutlin 3a or the inactive enantiomer 
Nutlin 3b for 8, 16 and 24 hours. Biological duplicates of the experiment were performed. 
We hybridized cDNA prepared from p202 cells untreated or treated with 10 uM of Nutlin 
3a at different time points to Affymetrix hgu133a chips containing approximately 22,000 
probe sets mapping to 15,000 known human genes. 
First, we explored the global topology of gene expression by using the 
significance analysis of microarrays (SAM) procedure to assess the statistical 
significance of differential expression of individual genes. We then compared the effects 
of Nultin treatment by clustering analysis of samples. 
An analysis using ANOVA showed that 796 genes were significantly influenced 
by the Nutlin treatment compared to untreated sample (p < 0.05). No changes in gene 
expression were detected in Nutlin 3b treated p53 cells. Figure 9 shows heat maps of 
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the main pathways affected by MDM2 inhibition. Based on our data, we conclude that in 
our system the biological effect of Nultin 3a is entirely p53 dependent. 
 
 
Cooperative Induction of Apoptosis Through p53 Signaling and mTOR Inhibition 
in Neuroblastoma. 
 
We sought to identify additional pathways to potentiate the p53 response. 
Mammalian target of rapamycin (mTOR) signaling pathway is active in neuroblastoma 
and mTOR inhibition has antiproliferative effects in vivo in neuroblastoma. It was 
recently demonstrated that two p53 target genes, Sestrin1 and Sestrin2, inhibit mTOR 
activity, linking genotoxic stress, p53 and the mTOR signaling pathway.  
Since Sestrin 1 and Sestrin 2 genes appeared to be significantly affected by 
Nutlin treatment, we investigate the role of Sestrin1 and Sestrin2 in p53-mediated 
apoptosis in neuroblastoma and the interaction of mTOR and p53 pathways after their 
simultaneous blockade using the mTOR inhibitor, Temsirolimus and the MDM2 inhibitor, 
Nutlin 3a.  
We show here that Sestrin1 and Sestrin2 genes are significantly upregulated in 
response to Nutlin in different neuroblastoma lines (SY5Y, MYCN non amplified, and 
IMR32, MYCN amplified) (Figures 10a and 10b). With MTT and Tunnel assays we 
demonstrate a p53-dependent synergistic effect of combined Nutlin 3a and Temsirolimus 
treatment on cell growth and apoptosis (Figures 11a and 11b).  
Flow cytometric analysis of the phospho-S6 ribosomal protein, read out for the 
blockade of the mTOR signaling, demonstrates a profound dephosphorylation of S6 in 
vitro when low dose Nutlin 3a is combined with Temsirolimus. Cooperative 
dephosphorylation of phospho S6 by Temsirolimus and Nutlin-3 suggests that mTOR 
inhibition and p53 activation strongly disrupt mTOR-mediated translational control, 
resulting in imbalanced expression of pro- and antiapoptotic proteins and unstable 
mitochondrial membrane potential (Figure 11c). 
Additional in vivo studies suggest that mTOR inhibition reduces tumor burden 
and phospho-S6 of neuroblastoma xenografts in nude mice.  We show here that the 
mTOR inhibitor, Temsirolimus, has profound effects on the growth of established 
neuroblastoma xenografts. To investigate the therapeutic effects of mTOR inhibition on 
neuroblastoma growth in vivo, nude mice carrying SH-SY5Y xenografts were treated 
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with CCI-779 20 mg/Kg/day for 12 days. Tumor growth was significantly inhibited after 
treatment with CCI-779 compared with untreated controls (Figures 12a and 12b).  
All these data support our hypothesis that MDM2 inhibition and Sestrin1 and 
Sestrin2 activation enhance the apoptotic response to mTOR blockade in 
neuroblastoma. As many pathway components are frequently affected in neuroblastoma, 
effective targeted therapies need to be developed that synergize through inhibition of 
multiple targets. 
These findings suggest that Nutlin 3a actively enhances mTOR signaling. Thus, 
a combination strategy aimed at activating p53 signaling and inhibiting mTOR signaling 
may represent a clinically potent approach to de novo and relapsed neuroblastoma. 
29 
 
4. DISCUSSION AND CONCLUSIONS  
 
Neuroblastoma remains a major therapeutic challenge in pediatric oncology 
despite decades of intensive research and therapeutic trials. This aggressive embryonal 
malignancy of neural crest origin has a peak age of onset of 22 months and accounts for 
approximately 11% of all pediatric cancers and 15% of all pediatric cancer deaths.   
With current treatment protocols, including high-dose chemotherapy with 
autologous stem cell transplant, radiation and surgery, about 80% of high-risk patients 
will go into remission.  However, the majority of these patients relapses and succumbs to 
therapy-resistant tumors producing a long-term survival of less than 50%.   
Studies using both cell culture and animal models of neuroblastoma are 
producing exciting new insights into its pathogenesis and molecular biology. This 
provides hope that rationally designed and targeted molecular therapeutics can be 
translated into less toxic and more effective treatments for neuroblastoma.  
A key feature of neuroblastoma is that it is uniformly p53 wild-type at diagnosis 
with intact intrinsic and extrinsic apoptotic mechanisms, including mitochondrial 
mediated cytochrome-c release and caspase activation.  While altered in vitro 
expression of mitochondrial associated pro- and anti-apoptotic Bcl-2 family members 
(e.g. Mcl-1 and the IAP (inhibitor of apoptosis) proteins (e.g. survivin)) are found in 
neuroblastoma cell lines, in vivo transgenic neuroblastoma and human xenograft models 
respond to genotoxic stress with robust wild-type p53-mediated responses, including 
stabilization of nuclear p53, increased p53 transcriptional activity, cell cycle arrest and 
apoptosis.  Clinically, genotoxic chemotherapy induces a rapid reduction in tumor 
volume in more than 80% of high-risk patients.  In those patients with chemo-resistant 
disease at diagnosis, mutant p53 is exceptionally rare, as more than 98% of de novo 
neuroblastomas have wild-type p53 by sequence analysis. 
An important clinical correlation is the rate of p53 mutations found in human 
neuroblastoma at relapse or after major chemotherapy treatment.  Available evidence 
from tumor cell lines derived from patient samples suggest that less than 15% of 
relapsed samples harbor mutant p53 (86).  However, the upstream regulators of p53 
appear to be frequently altered.  In particular, suppression of the MDM2 inhibitor 
p14ARF through multiple mechanisms (i.e. deletions, epigenetic silencing, etc.), 
amplification of MDM2, and elevated expression of ARF inhibitors BMI-1 (87) and 
TWIST-1 (88) are all found in subsets of relapsed samples 
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This suggests that inhibition of p53 activation upstream plays a critical role in 
neuroblastoma tumorigenesis and that therapeutic reversal of this inhibition should, in 
principle, lead to p53 activation and tumor death in vivo. Several in vitro and in vivo 
studies of MYCN demonstrate that this oncogene promotes cellular proliferation, 
metastasis, and genomic instability while also activating p53 mediated apoptotic stress 
responses. A deeper understanding of the mechanisms regulating the balance between 
proliferation and apoptosis in MYC oncogene stressed that cells will aid the rational 
design of better-targeted molecular therapies. 
As a central modulator of numerous essential cellular processes, p53 is 
positioned at the nexus of many upstream regulators. The primary inhibitor of p53 
activity is MDM2, an E3 ligase, which in complex with MDM4 and the E2 ligase UBcH5a 
(UBE2D1), acts to both ubiquitinate p53 and represses its transcriptional activity.  MDM2 
is in turn inhibited by the tumor suppressor p14ARF, which can bind to and prevent 
MDM2-mediated ubiquitination of p53, and activate p53 responses.   
In normal cells, tight feedback regulation of the ARF/MDM2/p53 axis controls p53 
activity through a host of protein modifications (e.g. phosphorylation, acetylation, 
sumoylation) as well as ubiquitination and de-ubiquitination and limits the effects of p53 
activation. 
In cancer cells with intact p53 activity such as neuroblastoma, MDM2 inhibition 
and subsequent rapid increases in nuclear p53 levels potently ‘re-activate’ dormant 
apoptotic pathways and rapidly induce apoptotic cell death. 
Detailed insight into control of p53 in normal and malignant cells has created an 
opportunity to develop rationally designed drugs such as Nutlin-3, which specifically 
blocks MDM2/p53 interactions with high affinity at low micromolar concentrations.  Such 
novel therapeutic approaches exploit the intact apoptotic machinery found in 
neuroblastoma and potentially other p53 wild-type malignancies. 
Clues to the mechanism of resistance to p53-mediated apoptosis come from the 
embryonal origins of neuroblastoma. Neuroblastoma arises from a subset of neural crest 
cells, which migrate from the central nervous system and are destined to form the 
enteric sympathetic nervous system and sympathetic ganglia. Rapid apoptosis within the 
ganglia micro-environment is a normal component of the final differentiation and 
modeling of the sympathetic system. This process is partially regulated in normal neural 
crest cells via PIK/AKT and transient MYCN signaling. In the well characterized MYCN-
transgenic mouse model of neuroblastoma, targeted expression of MYCN within the 
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neural crest lineage leads to hyper-proliferative ‘rests’ of PHOX2b / Nestin-positive 
neuroblasts in the maturing ganglia (89). These neuroblasts proliferate and transform 
despite the presence of wild-type p53 and strong developmentally programmed 
differentiation and apoptotic stimuli within the micro-environment (90). 
Our recent data from the compound transgenic mouse model demonstrate that 
this process is markedly restrained by Mdm2 haplo-insufficiency, suggesting that 
aberrant regulation of MDM2 by the MYCN transgene is an important component of 
overall suppression of p53 in neuroblastoma (91).   
A similar requirement for two functional alleles of Mdm2 to elicit maximal C-Myc 
driven tumorigenesis is also demonstrated in the eu-Myc driven mouse lymphoma model 
(92). Thus, in both normal and transformed neuroblasts, MYCN and MDM2 work 
together to inhibit apoptosis. This process is likely retained within neuroblastoma tumor 
stem cells (which share many attributes with their neural crest precursors), further 
supporting the therapeutic concept of using small molecule inhibitors to disrupt the 
MDM2/p53 interaction. 
In our study we demonstrate for the first time that MDM2 contributes to MYCN-
driven tumorigenesis in neural crest–derived neuroblastoma in vivo. The clinical 
implications of these data are very relevant.  
First, they strongly concur with two recent genetic analyses of neuroblastoma 
patient samples, suggesting that an activating single nucleotide polymorphism (SNP) in 
the human MDM2 promoter, SNP 309, correlates with a shorter time to relapse and a 
shorter time to death (52, 93). The SNP309 modifies an SP1 transcription factor binding 
site in the MDM2 promoter, increasing affinity for SP1 and subsequent MDM2 
transcription and attenuated p53 responses. Thus, elevated MDM2 transcription seems 
to significantly alter the behavior of human neuroblastomas. Importantly, the incidence of 
homozygosity for the activating SNP in neuroblastoma patients is twice that of controls, 
suggesting that elevated MDM2 levels contribute to neuroblastoma tumorigenesis. 
Second, after the induction of chemotherapy in the context of minimal residual disease, 
suppression of MDM2 activity with small-molecule inhibitors may prevent tumor regrowth 
and relapse, which is the primary cause of death in neuroblastoma.  
Since the majority of children with neuroblastoma succumb to chemoresistant 
relapse, we sought to determine the efficacy of targeting MDM2/p53 interaction in 
chemoresistant and sensitive cell lines, using the small molecule MDM2 inhibitor Nutlin-
3. 
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We demonstrate that neuroblastoma cells are extremely sensitive to MDM2 
inhibitors, such as Nutlin-3a, which activate p53-directed apoptosis. This small molecule 
inhibitor of MDM2 sensitizes neuroblastoma cell lines to chemotherapy agents such as 
Vp-16 and cytoxan, dramatically increasing the apoptotic response. These results are 
corroborated with in vivo tumor growth studies using a subcutaneous xenograft model 
system and oral administration of Nutlin-3.     
It has also recently been shown that the baseline ubiquitination status of p53 in 
neuroblastoma is elevated and that MDM2 inhibition may permit a cytoplasmic pool of 
mono-ubiquitinated p53 to activate mitochondrial dependent apoptotic pathways. Clearly 
increasing cytoplasmic levels of p53 past a certain threshold level rapidly triggers 
apoptosis in neuroblastoma and we have sought a better understanding of the 
mechanisms regulating this process for use in next generation therapies. 
Interesting a relevant study by Van Maerken et al (94), demonstrates comparable 
sub-micromolar IC50s for both p53 wild-type parental and a doxorubicin-resistant 
subclone (between 3 and 4 um) and a 10 fold higher IC50 for a p53 mutant (missense 
mutant 404T>G) vincrinstine-resistant subclone.  These elegant preclinical data are the 
first to demonstrate the efficacy of p53 reactivation in a chemoresistant model of 
neuroblastoma and set the stage for further clinical and preclinical investigations. 
A deeper understanding of the activation and stabilization of p53 in 
neuroblastoma will provide novel insights into mechanisms of apoptosis as well as 
therapeutic approaches to this fatal pediatric malignancy. Reconstitution of p53 function 
might open new therapeutic avenues against cancer. A more rigorous determination of 
the mechanisms governing induction of cell survival or death by p53 is crucial for the 
development of novel therapies since induction of cell-cycle arrest might allow DNA 
repair, thus protecting cancers from chemotherapeutic agents. These findings might help 
to design more effective and less toxic treatment strategies, manipulating the p53 
response so that pharmacological reactivation of p53 will favor apoptosis or growth 
arrest in tumor cells.  
In addition, Identification of pathways and/or factors governing the decision 
between apoptosis and growth arrest/DNA repair induced by p53 might help to develop 
tools that can modulate these pathways so that therapeutic reactivation of p53 by small 
molecules will kill tumor cells without detrimental effects on normal cells. 
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In this regard, we provide evidence for combination therapy that could improve 
the efficacy of mTORC1 inhibition, especially considering that agents that inhibit mTOR, 
like rapamycin and its analogs CCI-779 and RAD001, have been approved for clinical 
use and trials. 
Evidence indicates that non responsiveness to mTORC1 inhibition results from 
the release of negative feedback loops whereby pro-survival pathways upstream of 
mTOR are activated, such as the activation of Akt.  
We show here that low dose Nutlin 3 a strongly enhance the apoptosis mediated 
by the inhibition of mTOR signaling in neuroblastoma. This evidence has also an 
important clinical relevance, considering the cytotoxicity of the treatments with high dose 
mTOR inhibitors. In this context, low dose Nutlin 3a in addition to mTOR inhibition, can 
possibly improve neuroblastoma cell kill in conjunction with attenuated morbidity in 
children with neuroblastoma. 
In conclusion, it has become increasingly clear in recent years that 
inappropriately increased activity of MDM2 is the primary culprit for p53 inactivation in 
neuroblastoma cells. Preclinical work from our laboratory has shown that small-molecule 
MDM2 inhibitors are capable of eliciting potent antitumor effects against neuroblastoma 
by selectively and non-genotoxically reactivating p53. The fact that direct inactivating 
p53 mutations are rare regardless of stage of treatment, suggests that neuroblastoma 
has an innate requirement for baseline p53 activity (perhaps to resist oncogenic stress).  
This work lends further support to the therapeutic approach of using small-
molecule inhibitors of MDM2 to “de-repress” p53 in several phases of treatment. Further 
study will include combining MDM2 inhibition with additional molecular targets that are 
synergistic with the effects of Nutlin (i.e. HDAC inhibitors, MTOR inhibitors, and Aurora 
kinase inhibitors) in vivo. In vivo studies on tumor metastasis and angiogenesis which 
involve tumor/micro-environment interactions are ideally modeled in an orthotopic 
setting. The treatment of this type of neuroblastoma xenograft with MDM2 inhibitors 
alone and in combination with other therapies may well reveal additional synergistic 
sensitivities to this therapeutic approach and support rapid translation of this approach 
into the clinic.   
Modern chemotherapy based treatment for neuroblastoma has reached the 
maximum safe limits on dose intensity and incurs a high cost in terms of long-term and 
late side effects.  Despite aggressive treatment regimens, approximately half of the high-
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risk patients still relapse some time after completing therapy and about 20% of tumors 
are refractory to genotoxic treatment at diagnosis.   
Further in vivo modeling to optimize the best clinical use of MDM2 inhibition and 
phase one trials of this approach is urgently needed to define the safety and efficacy 
targeting the ARF/MDM2/p53 axis in children suffering from this aggressive cancer. 
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5. FIGURES AND TABLES  
*Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis. Van 
Maerken, J Vandesompele, A Rihani, A De Paepe and F Speleman. Cell Death and Differentiation (2009), 1–10. 
 
Figure 1. p53-MDM2 autoregulatory feedback loop.  
(a) The p53 protein induces expression of MDM2, which negatively regulates the stability and activity of p53, 
providing a means to keep p53 levels and activity low in unstressed cells and to switch off p53 at the end of 
a stress response. (b) The p53-mediated expression of MDM2 results from binding of p53 to response 
elements in the MDM2 gene and subsequent transactivation of MDM2. The domain structure of p53 is 
shown schematically. (c) The p53-inhibitory activity of MDM2 relies on multiple mechanisms. Binding of 
MDM2 to p53 conceals the TAD and consequently blocks the transcriptional activity of p53. MDM2 also 
recruits several corepressor proteins to p53, including HDAC1, CTBP2, YY1, and KAP1. The E3 ubiquitin 
ligase activity of MDM2 results in ubiquitination of lysine residues in the CTD of p53, preventing acetylation 
of p53, favoring nuclear export, and promoting proteasomal degradation.  MDM2 may also serve as a p53-
specific transcriptional silencer by binding and monoubiquitinating histone proteins in the proximity of p53-
responsive promoters. 
 
Figure 2. Generation of compound transgenic animals.  
(A) Breeding scheme used to generate matched sibling cohorts of Mdm2 haploinsufficient and Mdm2 wild-
type mice with the homozygous human MYCN transgene in Svj-129 mice. The haploinsufficient mice were 
backcrossed a minimum of seven generations into Svj-129 mice and then bred into the pTH-MYCN 
transgenic strain to obtain both Mdm2+/− and Mdm2+/+/MYCN+/+ compound transgenic mice. (B) 
Hematoxylin/eosin staining of both Mdm2+/− and Mdm2+/+ tumors shows an aggressive undifferentiated 
histologic finding. (C) Tumors in both Mdm2+/− and Mdm2+/+ were highly proliferative, and no differences in 
Ki-67 staining could be detected. 
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*Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A et al. Mdm2 deficiency suppresses MYCN-driven 
neuroblastoma tumorigenesis in vivo. Neoplasia 2009; 11:753–762. 
 
 
Figure 3. Tumor development in Mdm2+/− and Mdm2+/+ pTH-MYCN transgenic 
mice.  
Kaplan-Meier survival probability curves plotted for Mdm2+/+/MYCN (solid line) and Mdm2+/−/MYCN (dashed 
line) transgenic at 200 days of observation. (A) Combined analysis of 110 Mdm2+/− and 117 Mdm2+/+ mice 
shows a marked increase in median time to death (latency) and an overall decrease in tumor incidence (P < 
.001) consistent with the hypothesis that Mdm2 contributes directly to tumorigenesis in this model. (B) When 
analyzed according to sex, no difference in incidence was observed, but a significant increase in latency can 
be seen (P < .001). (C) For the female mice, an increase in latency but a pronounced decrease in incidence 
is now seen. No sex-dependent difference in tumor development was observed in the Mdm2+/+ mice (latency 
55 days [95% CI, 52-57 days]). Latency was 80 days (95% CI, 65-95 days) for the male Mdm2+/− mice and 
71 days (95% CI, 63-78 days) for the female Mdm2+/− mice.  Comparisons of survival and latency between 
sexes for each genotype were performed by Cox regression analysis. Mouse totals: Mdmd2+/−, 62 females 
and 48 males; Mdm2+/+, 58 females and 59 males. 
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Figure 4. Comparison of relative protein levels of MYCN, Mdm2, p53, p19Arf, p21, 
and Mdm4.  
We performed semiquantitative Western blot Mdm2, p53, p21, Mdm4, p19Arf, and MYCN in 12 tumors from 
each cohort. Western blots demonstrate that p53 protein levels are remarkably higher in Mdm2+/− tumors, 
whereas the mRNA levels do not differ. This is consistent with decreased Mdm2-mediated ubiquitination of 
p53 and relative stabilization of the protein compared with Mdm2+/+ tumors. 
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Figure 5. MDM2 inhibition induces rapid apoptotic response in neuroblastoma cell 
lines and primary tumor culture.  
Panel A and B.  At 24 hours all five neuroblastoma lines (IMR32, SK-N-JF, p202, p218) show significantly 
higher apoptosis rates compared to other solid tumor lines (MCF7, HCT116, HEPG2, SJSA-1). No apoptotic 
effect is detected in the p53 mutant line, SJ2-13, at each time point. Panel C.  p202 cells show a 
considerable apoptosis induction also at early time points (16 hrs). 
C 
B 
0
10
20
30
40
50
60
70
SJSA-1Hp202JF IMR32 p218 HCT116 
-/-
HCT116 
+/+
HEPG2MCF7 SJ2-13
Neuroblastoma
Control
N3A 48h
0
5
10
15
20
25
30
35
40
0 12 16 24
Time after treatment (hrs)
A
po
pt
o
si
s 
(%
)
MCF7
p202
SJ3-12
HCT116 +/+
39 
 
Figure 6. MDM2 inhibition induces rapid and transient p53 stabilization in 
neuroblastoma.   
Rapid and transient p53 stabilization occurs after treatment with Nutlin 3a in neuroblastoma cells as 
demonstrated by Western Blot. Neuroblastoma shows a unique kinetics of p53 stabilization compared to 
other non-neuroblastoma tumors. 
 
*Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, and Shohet JM. MDM2 inhibition sensitizes neuroblastoma to 
chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358–2365. 
 
Figure 7. Nutlin 3a potentiates the proapoptotic effects of conventional 
chemotherapeutic agents.  
IMR32 cells were incubated with increasing low-dose etoposide (VP-16; range 0.1– 1 umol/L) alone or in 
combination with low dose (2 umol/L) of Nutlin 3a for 24 h (A). IMR32 cells were incubated with low dose 
(0.1 umol/L) of etoposide alone, in combination with low dose (0.5 umol/L) of cisplatin, or in combination with 
low dose of cisplatin and Nutlin 3a (triple therapy) for 24 h (B). 
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*Barbieri et al. Submitted 2010. 
 
Figure 8. Experimental Design Schematic.  
RNA was extracted from p202 cells at the indicated timepoints.  The RNA was loaded onto an Affymetrics 
GeneChip representing more than 39,000 transcripts derived from approximately 33,000 well-substantiated 
human genes.  Gene expression was normalized at each timepoint against untreated cells (green arrows) 
and then compared between Nutlin-3a and Nutlin-3b treated cells (blue arrows).  Affymetrix Array tools and 
GeneSpring analysis of the microarray data generated a list of 176 genes whose expression is altered by 
Nutlin-3a exposure. 
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Figure 9. Heat maps of two of the main gene sets affected by MDM2 inhibition in 
neuroblastoma.  
Upregulation of Cell Proliferation gene set (Panel A), Downregulation of Hypoxia gene set (Panel  B). 
B 
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Figure 10. Sestrin1 and Sestrin2 are significantly upregulated in response to 
Nutlin3a in a p53-dependent fashion.  
Panel A. Heat map for Sestrin1 and Sestrin2 gene expression upon Nutlin treatment at different time points 
(3, 8, and 16 hours). Panel B. QPCR of SESN1 and SESN2 genes in response to Nutlin treatment. A p53 
neuroblastoma mutant line, Lan1, was used to confirm that the up-regulation of SESN1 and SESN2 in 
response to Nutlin is p53-dependent. Nutlin 3b was used as internal control. 
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Figure 11. Nutlin 3a acts synergistically with Temsirolimus to induce cell growth 
arrest and apoptosis 
Panel A. TdT assay - Low dose N3a (2uM) sensitize SY5Y cells to apoptosis induced by CCI-779. Panel B. 
MTT assay - Sensitivity of two neuroblastoma lines (CHLA 255 and SY5Y) to the combined treatment CCI-
779 and low dose N3a. Panel C. Analysis of Phospho-S6 by Flowcytometry – Low dose N3a is able to 
induce S6 dephosphorylation with an effect similar to CCI-779. 
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Figure 12. Effect of mTOR inhibitor on neuroblastoma xenograft growth in vivo. 
10 Nude mice engrafted with 1 X106 SH SY5Ycells orthotopically were randomized to receive CCI-779 (20 
mg/kg, intraperitoneally, daily for 12 days) or no treatment (A). Comparison of tumor volumes from mice 
treated with CCI-779 or untreated controls (mean±s.d) (B).  
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Table  1 
 
*Karen H. Vousden and Kevin M. Ryan. p53 and metabolism. Nature Reviews Cancer, 17 September 2009. 
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